Gambardella S, Tamburrano G, Giaccari A, Frontoni S, Lala A, Spallone V, Barini A, Felici M G, Menzinger G
Cattedra di Malattie del Ricambio, Università Tor Vergata, Roma, Italy.
J Endocrinol Invest. 1989 Mar;12(3):163-70. doi: 10.1007/BF03349953.
Dexamethasone inhibits ACTH secretion in the pituitary corticotropic cells of normal subjects; this ability is variously affected in Cushing's syndrome. The iv infusion of dexamethasone is not time consuming, nor it is influenced by the variability of intestinal absorption or hepatic metabolism, as occurs with oral administration. Iv dexamethasone (1.5 mg/h) over 7 h and an ACTH bolus at the 6th h were administered to 17 patients with Cushing's disease, 3 patients with Cushing's syndrome (2 with adrenal adenoma, 1 with ectopic ACTH secretion) and 13 normal subjects. After 4 days the 20 patients were also given the standard oral low-dose and high-dose dexamethasone test. Two h after starting the drug infusion, cortisol concentrations were inhibited by more than 50% in each control subject. In contrast, in all but one patient they remained higher than 50% over the baseline. At the 6th heach control subject and 15 of the 17 patients with Cushing's disease showed an inhibition of plasma cortisol concentration which was greater than 50%. Inhibition was less than 50% in 2 patients with Cushing's disease and in the 3 patients with non-pituitary dependent Cushing's syndrome. The sensitivity and specificity of this test are comparable with those of the dexamethasone oral test. Although statistically significant, results obtained from ACTH bolus were not sufficiently discriminating. If studies conducted on a larger population confirm these preliminary data, the rapidity and reliability of the dexamethasone infusion test could make it an important new tool in diagnosing Cushing's syndrome.
地塞米松可抑制正常受试者垂体促肾上腺皮质激素细胞分泌促肾上腺皮质激素(ACTH);在库欣综合征中,这种能力受到不同程度的影响。静脉输注地塞米松并不耗时,也不受肠道吸收或肝脏代谢变异性的影响,而口服给药则会出现这种情况。对17例库欣病患者、3例库欣综合征患者(2例肾上腺腺瘤、1例异位ACTH分泌)和13名正常受试者静脉输注地塞米松(1.5mg/h),持续7小时,并在第6小时给予ACTH推注。4天后,这20名患者还接受了标准的口服低剂量和高剂量地塞米松试验。开始药物输注2小时后,每个对照受试者的皮质醇浓度被抑制超过50%。相比之下,除1例患者外,所有患者的皮质醇浓度均比基线水平高50%以上。在第6小时,每个对照受试者以及17例库欣病患者中的15例血浆皮质醇浓度抑制率大于50%。2例库欣病患者和3例非垂体依赖性库欣综合征患者的抑制率小于50%。该试验的敏感性和特异性与地塞米松口服试验相当。尽管ACTH推注的结果具有统计学意义,但鉴别能力不足。如果对更大规模人群进行的研究证实了这些初步数据,地塞米松输注试验的快速性和可靠性可能使其成为诊断库欣综合征的一项重要新工具。